annual EBITDA:
-$561.51M-$385.84M(-219.64%)Summary
- As of today (September 10, 2025), ARWR annual EBITDA is -$561.51 million, with the most recent change of -$385.84 million (-219.64%) on September 30, 2024.
- During the last 3 years, ARWR annual EBITDA has fallen by -$428.93 million (-323.53%).
- ARWR annual EBITDA is now -955.57% below its all-time high of $65.63 million, reached on September 30, 2019.
Performance
ARWR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$159.33M-$546.61M(-141.14%)Summary
- As of today (September 10, 2025), ARWR quarterly EBITDA is -$159.33 million, with the most recent change of -$546.61 million (-141.14%) on June 30, 2025.
- Over the past year, ARWR quarterly EBITDA has increased by +$12.03 million (+7.02%).
- ARWR quarterly EBITDA is now -141.14% below its all-time high of $387.29 million, reached on March 31, 2025.
Performance
ARWR quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$85.40M+$12.03M(+12.35%)Summary
- As of today (September 10, 2025), ARWR TTM EBITDA is -$85.40 million, with the most recent change of +$12.03 million (+12.35%) on June 30, 2025.
- Over the past year, ARWR TTM EBITDA has increased by +$444.38 million (+83.88%).
- ARWR TTM EBITDA is now -230.12% below its all-time high of $65.63 million, reached on September 30, 2019.
Performance
ARWR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ARWR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -219.6% | +7.0% | +83.9% |
| 3 y3 years | -323.5% | -126.6% | +42.8% |
| 5 y5 years | -955.6% | -1005.7% | -203.3% |
ARWR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -323.5% | at low | -141.1% | +7.0% | at high | +85.9% |
| 5 y | 5-year | -955.6% | at low | -141.1% | +7.0% | -203.3% | +85.9% |
| alltime | all time | -955.6% | at low | -141.1% | +7.0% | -230.1% | +85.9% |
ARWR EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$159.33M(-141.1%) | -$85.40M(-12.3%) |
| Mar 2025 | - | $387.29M(-348.0%) | -$97.43M(-83.9%) |
| Dec 2024 | - | -$156.18M(-0.6%) | -$606.38M(+4.1%) |
| Sep 2024 | -$561.51M(+219.6%) | -$157.18M(-8.3%) | -$582.49M(+9.9%) |
| Jun 2024 | - | -$171.36M(+40.8%) | -$529.78M(+15.7%) |
| Mar 2024 | - | -$121.67M(-8.0%) | -$457.85M(+60.5%) |
| Dec 2023 | - | -$132.28M(+26.6%) | -$285.35M(+48.2%) |
| Sep 2023 | -$175.67M(+8.2%) | -$104.47M(+5.1%) | -$192.51M(+13.8%) |
| Jun 2023 | - | -$99.43M(-295.6%) | -$169.21M(+20.8%) |
| Mar 2023 | - | $50.84M(-228.9%) | -$140.09M(-4.6%) |
| Dec 2022 | - | -$39.45M(-51.4%) | -$146.78M(-12.7%) |
| Sep 2022 | -$162.29M(+22.4%) | -$81.17M(+15.5%) | -$168.09M(+12.6%) |
| Jun 2022 | - | -$70.31M(-259.3%) | -$149.30M(+37.1%) |
| Mar 2022 | - | $44.14M(-172.7%) | -$108.86M(-39.3%) |
| Dec 2021 | - | -$60.75M(-2.6%) | -$179.33M(+27.4%) |
| Sep 2021 | -$132.58M(+52.0%) | -$62.38M(+108.9%) | -$140.81M(+11.1%) |
| Jun 2021 | - | -$29.87M(+13.4%) | -$126.77M(+13.9%) |
| Mar 2021 | - | -$26.33M(+18.5%) | -$111.32M(+5.2%) |
| Dec 2020 | - | -$22.23M(-54.0%) | -$105.85M(+21.4%) |
| Sep 2020 | -$87.22M(-232.9%) | -$48.34M(+235.5%) | -$87.22M(+209.8%) |
| Jun 2020 | - | -$14.41M(-31.0%) | -$28.15M(-580.6%) |
| Mar 2020 | - | -$20.87M(+480.7%) | $5.86M(-88.3%) |
| Dec 2019 | - | -$3.59M(-133.5%) | $49.91M(-23.9%) |
| Sep 2019 | $65.63M(-228.1%) | $10.72M(-45.3%) | $65.63M(+45.9%) |
| Jun 2019 | - | $19.60M(-15.5%) | $44.97M(+323.2%) |
| Mar 2019 | - | $23.19M(+91.3%) | $10.63M(-140.2%) |
| Dec 2018 | - | $12.12M(-222.0%) | -$26.44M(-48.4%) |
| Sep 2018 | -$51.24M(+58.6%) | -$9.94M(-32.6%) | -$51.24M(+1.7%) |
| Jun 2018 | - | -$14.74M(+6.2%) | -$50.39M(+25.4%) |
| Mar 2018 | - | -$13.88M(+9.5%) | -$40.20M(+28.6%) |
| Dec 2017 | - | -$12.67M(+39.3%) | -$31.26M(-3.2%) |
| Sep 2017 | -$32.31M(-57.7%) | -$9.10M(+99.8%) | -$32.31M(-32.7%) |
| Jun 2017 | - | -$4.55M(-7.9%) | -$47.97M(-22.6%) |
| Mar 2017 | - | -$4.94M(-64.0%) | -$61.94M(-20.0%) |
| Dec 2016 | - | -$13.72M(-44.6%) | -$77.46M(-5.9%) |
| Sep 2016 | -$76.43M(-18.4%) | -$24.76M(+33.7%) | -$82.29M(+2.9%) |
| Jun 2016 | - | -$18.52M(-9.5%) | -$80.01M(+4.3%) |
| Mar 2016 | - | -$20.46M(+10.3%) | -$76.74M(+1.9%) |
| Dec 2015 | - | -$18.55M(-17.5%) | -$75.32M(-7.7%) |
| Sep 2015 | -$93.64M(+88.2%) | -$22.48M(+47.4%) | -$81.60M(+6.5%) |
| Jun 2015 | - | -$15.25M(-19.9%) | -$76.65M(+3.8%) |
| Mar 2015 | - | -$19.04M(-23.3%) | -$73.83M(+12.5%) |
| Dec 2014 | - | -$24.83M(+41.6%) | -$65.60M(+38.5%) |
| Sep 2014 | -$49.76M(+131.1%) | -$17.54M(+41.1%) | -$47.38M(+31.5%) |
| Jun 2014 | - | -$12.42M(+14.9%) | -$36.03M(+27.6%) |
| Mar 2014 | - | -$10.82M(+63.7%) | -$28.23M(+26.3%) |
| Dec 2013 | - | -$6.61M(+6.9%) | -$22.35M(+11.2%) |
| Sep 2013 | -$21.53M(+11.3%) | -$6.18M(+33.5%) | -$20.11M(+6.6%) |
| Jun 2013 | - | -$4.63M(-6.4%) | -$18.86M(-8.5%) |
| Mar 2013 | - | -$4.94M(+13.3%) | -$20.61M(+2.5%) |
| Dec 2012 | - | -$4.36M(-11.6%) | -$20.12M(+4.4%) |
| Sep 2012 | -$19.34M | -$4.93M(-22.7%) | -$19.27M(+12.1%) |
| Jun 2012 | - | -$6.38M(+43.5%) | -$17.19M(+37.4%) |
| Mar 2012 | - | -$4.44M(+26.5%) | -$12.51M(+27.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | - | -$3.51M(+23.4%) | -$9.82M(+36.5%) |
| Sep 2011 | -$9.56M(+72.1%) | -$2.85M(+67.2%) | -$7.19M(+8.7%) |
| Jun 2011 | - | -$1.70M(-2.7%) | -$6.61M(-5.5%) |
| Mar 2011 | - | -$1.75M(+97.4%) | -$6.99M(-4.1%) |
| Dec 2010 | - | -$887.00K(-60.9%) | -$7.29M(-14.1%) |
| Sep 2010 | -$5.56M(-70.1%) | -$2.27M(+8.8%) | -$8.49M(-10.1%) |
| Jun 2010 | - | -$2.09M(+1.7%) | -$9.45M(-1.4%) |
| Mar 2010 | - | -$2.05M(-1.5%) | -$9.58M(-10.5%) |
| Dec 2009 | - | -$2.08M(-35.5%) | -$10.71M(-21.3%) |
| Sep 2009 | -$18.57M(-45.2%) | -$3.23M(+45.2%) | -$13.62M(-37.7%) |
| Jun 2009 | - | -$2.22M(-30.0%) | -$21.85M(-25.3%) |
| Mar 2009 | - | -$3.18M(-36.3%) | -$29.25M(-11.0%) |
| Dec 2008 | - | -$4.99M(-56.5%) | -$32.85M(-4.7%) |
| Sep 2008 | -$33.87M(-8.3%) | -$11.46M(+19.0%) | -$34.46M(+0.3%) |
| Jun 2008 | - | -$9.63M(+42.1%) | -$34.36M(-9.3%) |
| Mar 2008 | - | -$6.78M(+2.7%) | -$37.88M(-3.6%) |
| Dec 2007 | - | -$6.60M(-41.9%) | -$39.30M(+6.4%) |
| Sep 2007 | -$36.95M(+88.5%) | -$11.36M(-13.6%) | -$36.94M(+11.6%) |
| Jun 2007 | - | -$13.14M(+60.3%) | -$33.09M(+36.7%) |
| Mar 2007 | - | -$8.20M(+93.2%) | -$24.20M(+22.4%) |
| Dec 2006 | - | -$4.24M(-43.5%) | -$19.77M(+2.2%) |
| Sep 2006 | -$19.60M(+119.0%) | -$7.51M(+76.5%) | -$19.35M(+43.4%) |
| Jun 2006 | - | -$4.25M(+12.9%) | -$13.50M(+8.7%) |
| Mar 2006 | - | -$3.77M(-1.5%) | -$12.42M(+18.0%) |
| Dec 2005 | - | -$3.82M(+131.0%) | -$10.52M(+23.0%) |
| Sep 2005 | -$8.95M(+242.1%) | -$1.66M(-47.8%) | -$8.55M(+2.8%) |
| Jun 2005 | - | -$3.17M(+69.3%) | -$8.32M(+44.8%) |
| Mar 2005 | - | -$1.87M(+0.9%) | -$5.75M(+30.4%) |
| Dec 2004 | - | -$1.86M(+30.2%) | -$4.41M(+63.6%) |
| Sep 2004 | -$2.62M(+2674.2%) | -$1.43M(+140.0%) | -$2.69M(+108.8%) |
| Jun 2004 | - | -$594.10K(+11.9%) | -$1.29M(+81.9%) |
| Mar 2004 | - | -$531.10K(+273.2%) | -$709.40K(+244.2%) |
| Dec 2003 | - | -$142.30K(+529.6%) | -$206.10K(+118.3%) |
| Sep 2003 | -$94.30K(-93.3%) | -$22.60K(+68.7%) | -$94.40K(+39.2%) |
| Jun 2003 | - | -$13.40K(-51.8%) | -$67.80K(-31.0%) |
| Mar 2003 | - | -$27.80K(-9.2%) | -$98.30K(+5.8%) |
| Dec 2002 | - | -$30.60K(-865.0%) | -$92.90K(+5.6%) |
| Sep 2002 | -$1.41M(+1270.1%) | $4000.00(-109.1%) | -$88.00K(-5.0%) |
| Jun 2002 | - | -$43.90K(+96.0%) | -$92.60K(+44.2%) |
| Mar 2002 | - | -$22.40K(-12.8%) | -$64.20K(-2.1%) |
| Dec 2001 | - | -$25.70K(+4183.3%) | -$65.60K(-10.0%) |
| Sep 2001 | -$102.70K(+1.1%) | -$600.00(-96.1%) | -$72.90K(-26.0%) |
| Jun 2001 | - | -$15.50K(-34.9%) | -$98.50K(-5.4%) |
| Mar 2001 | - | -$23.80K(-27.9%) | -$104.10K(+0.4%) |
| Dec 2000 | - | -$33.00K(+26.0%) | -$103.70K(+2.1%) |
| Sep 2000 | -$101.60K(+111.2%) | -$26.20K(+24.2%) | -$101.60K(+36.9%) |
| Jun 2000 | - | -$21.10K(-9.8%) | -$74.20K(+6.5%) |
| Mar 2000 | - | -$23.40K(-24.3%) | -$69.70K(+15.2%) |
| Dec 1999 | - | -$30.90K(-2675.0%) | -$60.50K(+104.4%) |
| Sep 1999 | -$48.10K(+218.5%) | $1200.00(-107.2%) | -$29.60K(-3.9%) |
| Jun 1999 | - | -$16.60K(+16.9%) | -$30.80K(+116.9%) |
| Mar 1999 | - | -$14.20K | -$14.20K |
| Sep 1998 | -$15.10K(-72.4%) | - | - |
| Sep 1997 | -$54.80K | - | - |
FAQ
- What is Arrowhead Pharmaceuticals, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Arrowhead Pharmaceuticals, Inc.?
- What is Arrowhead Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Arrowhead Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Arrowhead Pharmaceuticals, Inc.?
- What is Arrowhead Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Arrowhead Pharmaceuticals, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Arrowhead Pharmaceuticals, Inc.?
- What is Arrowhead Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Arrowhead Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of ARWR is -$561.51M
What is the all time high annual EBITDA for Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. all-time high annual EBITDA is $65.63M
What is Arrowhead Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, ARWR annual EBITDA has changed by -$385.84M (-219.64%)
What is Arrowhead Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of ARWR is -$159.33M
What is the all time high quarterly EBITDA for Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. all-time high quarterly EBITDA is $387.29M
What is Arrowhead Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, ARWR quarterly EBITDA has changed by +$12.03M (+7.02%)
What is Arrowhead Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of ARWR is -$85.40M
What is the all time high TTM EBITDA for Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. all-time high TTM EBITDA is $65.63M
What is Arrowhead Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, ARWR TTM EBITDA has changed by +$444.38M (+83.88%)